Fate Therapeutics
FATE
A$1.99
Share price
4.84%
Change (1 day)
-75.87%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : A$0.16 Billion
According to Fate Therapeutics 's latest financial reports the company's total liabilities are A$0.16 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Fate Therapeutics - Total liabilities on balance sheet (from 2012 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | A$0.19 B | -3.05% |
| 2023-12-31 | A$0.20 B | -37.89% |
| 2022-12-31 | A$0.32 B | -2.68% |
| 2021-12-31 | A$0.33 B | 8.11% |
| 2020-12-31 | A$0.30 B | 276.79% |
| 2019-12-31 | A$82.15 M | 10.1% |
| 2018-12-31 | A$74.61 M | 107.28% |
| 2017-12-31 | A$35.99 M | 18.51% |
| 2016-12-31 | A$30.37 M | -26.05% |
| 2015-12-31 | A$41.07 M | 47.15% |
| 2014-12-31 | A$27.91 M | 425.8% |
| 2013-12-31 | A$5.3 M | -91.37% |
| 2012-12-31 | A$61.49 M | 7.71% |
| 2011-12-31 | A$57.08 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | A$3.55 B | 2,006.51% | 🇺🇸 USA |
 Becton Dickinson BDX | A$44.79 B | 26,406.20% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | A$4.35 B | 2,476.75% | 🇺🇸 USA |
 Avidity Biosciences RNA | A$0.19 B | 18.22% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | A$1.76 B | 944.79% | 🇺🇸 USA |